Early stage commercialization assessments help you determine the patentability and marketability of your technologies, saving you money and increasing your success rate. Work with us from setting a timeline to product launch to forming a go-to-market strategy.Read More
services and platforms to speed innovation to market
Boston Mountain Biotech is a contract research organization focused on moving technology from the lab to the commercial space quickly and cost effectively. Our team of experts excels at helping you obtain the research you need to succeed.
We also develop and patent technology for a new protein expression and purification platform, the Lotus® technology allows manufacturers to reduce host cell protein (HCP) load in downstream processing through cell line modifications. This platform to reduce HCPs in bacterial cell lines simplifies the development and manufacturing of recombinant protein therapeutics, vaccines and enzymes. At BMB, we are revolutionizing the pharmaceutical industry by providing protein purification solutions that result in new drugs moving from development to patient faster while simultaneously lowering the cost of manufacturing.
Boston Mountain Biotech provides services from upstream cell line development to downstream protein purification and all the steps in between.
Many of our customers are brilliant research scientists in areas outside of bioprocessing. It is our goal to support their research by allowing them to focus on what they do best, and allow us to take care of the rest. Our facilities are equipped to handle both the small scale needs of academic and clinical researchers as well as the larger scale needs of research teams entering pre-IND development. Some of our services include biotechnology laboratory research, commercialization assessments and intellectual property strategy.
Despite major advancements in biopharmaceutical manufacturing, protein purification remains one of the most costly and restrictive aspects of production that impacts negatively impacting start-ups and Fortune 500 companies alike.
At BMB, we are tackling this challenge by developing the Lotus® platform which links downstream contaminating host cell proteins (HCPs) to potential upstream cell line modifications. The Lotus platform accomplishes this by identifying the cellular proteins that exert the greatest burden on downstream processing and then shutting off these genes in the production strain. This platform could be readily implemented across much of the biomanufacturing industry,with the potential to reduce costs to consumers in the ever-burgeoning healthcare market and ease the time and investment required to bring new therapeutics to market.